1Davis MP,Walsh D.Epidemiology of cancer pain and factors influencing poor pain control.Am J Hosp Palliat Care,2004,21:137-142.
2Kalso E,Vainio A.Morphine and oxycodone hydrochloride in the management of cancer pain.Clin Pharmacol Ther,1990,47:639-646.
3Finkel JC,Finley A,Greco C.Transdermal fentanyl in the management of children with chronic severe pain:results from an international study.Cancer,2005,104:2847-2857.
4Skaer TL.Transdermal opioids for cancer pain.Health Qual Life Outcomes,2006,4:24.
5Hanna M,Tuca A,Thipphawong J,et al.An open-label,1-year extension study of the longterm safety and efficacy of once-daily OROS.hydromorphone in patients with chronic cancer pain.BMC Palliat Care,2009,8:14.
6Carter NJ,Keating GM.OROS hydromorphone prolonged release:a review of its use in the management of chronic,moderate to severe pain.CNS Drugs,2010,24:337-361.
7Mercadante S,Casuccio A,Fulfaro F,et al.Switching from morphine to methadone to improve analgesia and tolerability in cancer patients.A prospective study.J Clin Oncol,2001,19:2898-2904.
8Rosenthal NR,Silverfield JC,Wu SC,et al.Tramadol/acetaminophen combination tablets for the treatment of pain associated with osteoarthritis flare in an elderly patient population.J Am Geriatr Soc,2004,52:374-380.
9Rodriguez RF,Castillo JM,Castillo MP,et al.Codeine/acetaminophen and hydrocodone/acetaminophen combination tablets for the management of chronic cancer pain in adults:a 23-day,prospective,double-blind,randomized,parallel-group study.Clin Ther,2007,29:581-587.
10Rodriguez RF,Bravo LE,Castro F,et al.Incidence of weak opioids adverse events in the management of cancer pain:a double-blind comparative trial.J Palliat Med,2007,10:56-60.
